Aadi Bioscience Inc
AADI - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$184.71M
Close$
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $184.71 Million |
|---|---|
| Enterprise Value | $99.48 Million |
| Earnings per Share | $-0.03 |
| Beta | 0.34 |
| Outstanding Shares | 82,886,196 |
Return
| Return on Equity | -43.64% |
|---|---|
| Return on Assets | -41.15% |
| Return on Invested Capital | -46.25% |
Valuation & Multiples
| P/E Ratio | -2.89 |
|---|---|
| PEG | 4.23 |
| Price to Sales | - |
| Price to Book Ratio | 1.03 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -1.18 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Last Earnings Call
Report Date
March 12, 2026
EPS Estimate
-
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 47.65%▲ 5.99% |
|---|---|
| Total Invested | $79.25M▲ 45.83% |
| Investors Holding | 47▲ 8.00% |
About Aadi Bioscience Inc
12 employees
CEO: David J. Lennon
Aerpio Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing compounds that activate Tie2 for indications in which the Company believes that activation of Tie2 may have therapeutic potential. The Company's lead compo...